Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Free Cash Flow (2020 - 2025)

Bolt Biotherapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$9.8 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 29.82% year-over-year to -$9.8 million; the TTM value through Sep 2025 reached -$47.2 million, up 22.91%, while the annual FY2024 figure was -$61.3 million, 12.11% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$9.8 million at Bolt Biotherapeutics, down from -$9.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.2 million in Q2 2021 and bottomed at -$24.9 million in Q1 2022.
  • The 5-year median for Free Cash Flow is -$16.2 million (2024), against an average of -$15.9 million.
  • The largest annual shift saw Free Cash Flow soared 69.14% in 2021 before it plummeted 388.2% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$19.5 million in 2021, then increased by 7.19% to -$18.1 million in 2022, then increased by 21.31% to -$14.3 million in 2023, then dropped by 0.83% to -$14.4 million in 2024, then surged by 31.86% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Free Cash Flow are -$9.8 million (Q3 2025), -$9.6 million (Q2 2025), and -$13.4 million (Q1 2025).